vs

Side-by-side financial comparison of Consensus Cloud Solutions, Inc. (CCSI) and PROCEPT BioRobotics Corp (PRCT). Click either name above to swap in a different company.

Consensus Cloud Solutions, Inc. is the larger business by last-quarter revenue ($87.1M vs $83.1M, roughly 1.0× PROCEPT BioRobotics Corp). Consensus Cloud Solutions, Inc. runs the higher net margin — 23.5% vs -38.1%, a 61.6% gap on every dollar of revenue. On growth, PROCEPT BioRobotics Corp posted the faster year-over-year revenue change (20.2% vs 0.1%). Over the past eight quarters, PROCEPT BioRobotics Corp's revenue compounded faster (24.8% CAGR vs -0.6%).

Consensus Cloud Solutions, Inc. is a provider of cloud-based secure information delivery and digital workflow solutions. Its core offerings include encrypted digital fax, secure document exchange, and process automation tools, serving clients across healthcare, legal, financial services and enterprise sectors, with a primary operating market in North America.

PROCEPT BioRobotics Corp is a medical tech firm developing and commercializing robotic surgical solutions for urological care. Its flagship AquaBeam system provides image-guided minimally invasive therapy for benign prostatic hyperplasia, serving providers and patients across North America, Europe and global markets.

CCSI vs PRCT — Head-to-Head

Bigger by revenue
CCSI
CCSI
1.0× larger
CCSI
$87.1M
$83.1M
PRCT
Growing faster (revenue YoY)
PRCT
PRCT
+20.1% gap
PRCT
20.2%
0.1%
CCSI
Higher net margin
CCSI
CCSI
61.6% more per $
CCSI
23.5%
-38.1%
PRCT
Faster 2-yr revenue CAGR
PRCT
PRCT
Annualised
PRCT
24.8%
-0.6%
CCSI

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CCSI
CCSI
PRCT
PRCT
Revenue
$87.1M
$83.1M
Net Profit
$20.5M
$-31.6M
Gross Margin
80.0%
64.9%
Operating Margin
41.1%
-4.1%
Net Margin
23.5%
-38.1%
Revenue YoY
0.1%
20.2%
Net Profit YoY
13.5%
-27.9%
EPS (diluted)
$1.06
$-0.56

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CCSI
CCSI
PRCT
PRCT
Q1 26
$83.1M
Q4 25
$87.1M
$76.4M
Q3 25
$87.8M
$83.3M
Q2 25
$87.7M
$79.2M
Q1 25
$87.1M
$69.2M
Q4 24
$87.0M
$68.2M
Q3 24
$87.8M
$58.4M
Q2 24
$87.5M
$53.4M
Net Profit
CCSI
CCSI
PRCT
PRCT
Q1 26
$-31.6M
Q4 25
$20.5M
$-29.8M
Q3 25
$22.1M
$-21.4M
Q2 25
$20.8M
$-19.6M
Q1 25
$21.2M
$-24.7M
Q4 24
$18.1M
$-18.9M
Q3 24
$21.1M
$-21.0M
Q2 24
$23.9M
$-25.6M
Gross Margin
CCSI
CCSI
PRCT
PRCT
Q1 26
64.9%
Q4 25
80.0%
60.6%
Q3 25
80.0%
64.8%
Q2 25
79.9%
65.4%
Q1 25
79.3%
63.9%
Q4 24
79.5%
64.0%
Q3 24
79.9%
63.2%
Q2 24
80.4%
59.0%
Operating Margin
CCSI
CCSI
PRCT
PRCT
Q1 26
-4.1%
Q4 25
41.1%
-40.6%
Q3 25
43.2%
-27.8%
Q2 25
44.5%
-28.0%
Q1 25
43.0%
-39.7%
Q4 24
38.4%
-28.9%
Q3 24
43.8%
-38.4%
Q2 24
45.6%
-50.3%
Net Margin
CCSI
CCSI
PRCT
PRCT
Q1 26
-38.1%
Q4 25
23.5%
-39.1%
Q3 25
25.2%
-25.7%
Q2 25
23.7%
-24.7%
Q1 25
24.3%
-35.8%
Q4 24
20.8%
-27.6%
Q3 24
24.1%
-35.9%
Q2 24
27.3%
-48.0%
EPS (diluted)
CCSI
CCSI
PRCT
PRCT
Q1 26
$-0.56
Q4 25
$1.06
$-0.54
Q3 25
$1.15
$-0.38
Q2 25
$1.07
$-0.35
Q1 25
$1.07
$-0.45
Q4 24
$0.92
$-0.34
Q3 24
$1.09
$-0.40
Q2 24
$1.24
$-0.50

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CCSI
CCSI
PRCT
PRCT
Cash + ST InvestmentsLiquidity on hand
$74.7M
$245.6M
Total DebtLower is stronger
$558.4M
$51.7M
Stockholders' EquityBook value
$13.8M
$347.7M
Total Assets
$663.8M
$487.1M
Debt / EquityLower = less leverage
40.54×
0.15×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CCSI
CCSI
PRCT
PRCT
Q1 26
$245.6M
Q4 25
$74.7M
$286.5M
Q3 25
$97.6M
$294.3M
Q2 25
$57.9M
$302.7M
Q1 25
$53.4M
$316.2M
Q4 24
$33.5M
$333.7M
Q3 24
$54.6M
$196.8M
Q2 24
$49.2M
$214.1M
Total Debt
CCSI
CCSI
PRCT
PRCT
Q1 26
$51.7M
Q4 25
$558.4M
$51.6M
Q3 25
$578.6M
$51.6M
Q2 25
$578.2M
$51.5M
Q1 25
$583.7M
$51.5M
Q4 24
$593.0M
$51.5M
Q3 24
$612.5M
$51.4M
Q2 24
$642.8M
$51.4M
Stockholders' Equity
CCSI
CCSI
PRCT
PRCT
Q1 26
$347.7M
Q4 25
$13.8M
$365.9M
Q3 25
$-2.6M
$380.3M
Q2 25
$-26.5M
$385.8M
Q1 25
$-49.4M
$389.2M
Q4 24
$-79.5M
$402.2M
Q3 24
$-93.2M
$241.2M
Q2 24
$-124.4M
$251.8M
Total Assets
CCSI
CCSI
PRCT
PRCT
Q1 26
$487.1M
Q4 25
$663.8M
$508.1M
Q3 25
$675.0M
$511.5M
Q2 25
$641.5M
$513.1M
Q1 25
$629.6M
$519.4M
Q4 24
$602.2M
$534.0M
Q3 24
$622.5M
$374.1M
Q2 24
$608.5M
$374.4M
Debt / Equity
CCSI
CCSI
PRCT
PRCT
Q1 26
0.15×
Q4 25
40.54×
0.14×
Q3 25
0.14×
Q2 25
0.13×
Q1 25
0.13×
Q4 24
0.13×
Q3 24
0.21×
Q2 24
0.20×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CCSI
CCSI
PRCT
PRCT
Operating Cash FlowLast quarter
$15.2M
Free Cash FlowOCF − Capex
$7.3M
FCF MarginFCF / Revenue
8.4%
Capex IntensityCapex / Revenue
9.1%
Cash ConversionOCF / Net Profit
0.74×
TTM Free Cash FlowTrailing 4 quarters
$105.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CCSI
CCSI
PRCT
PRCT
Q1 26
Q4 25
$15.2M
$-10.3M
Q3 25
$51.6M
$-6.6M
Q2 25
$28.3M
$-15.0M
Q1 25
$40.9M
$-17.0M
Q4 24
$11.1M
$-32.4M
Q3 24
$41.6M
$-18.8M
Q2 24
$24.4M
$-15.7M
Free Cash Flow
CCSI
CCSI
PRCT
PRCT
Q1 26
Q4 25
$7.3M
$-12.2M
Q3 25
$44.4M
$-9.5M
Q2 25
$20.3M
$-17.8M
Q1 25
$33.7M
$-18.8M
Q4 24
$3.1M
$-33.6M
Q3 24
$33.6M
$-19.0M
Q2 24
$15.8M
$-16.8M
FCF Margin
CCSI
CCSI
PRCT
PRCT
Q1 26
Q4 25
8.4%
-15.9%
Q3 25
50.6%
-11.4%
Q2 25
23.2%
-22.5%
Q1 25
38.7%
-27.2%
Q4 24
3.6%
-49.2%
Q3 24
38.3%
-32.6%
Q2 24
18.1%
-31.4%
Capex Intensity
CCSI
CCSI
PRCT
PRCT
Q1 26
Q4 25
9.1%
2.4%
Q3 25
8.2%
3.4%
Q2 25
9.1%
3.5%
Q1 25
8.3%
2.7%
Q4 24
9.2%
1.7%
Q3 24
9.1%
0.4%
Q2 24
9.8%
2.0%
Cash Conversion
CCSI
CCSI
PRCT
PRCT
Q1 26
Q4 25
0.74×
Q3 25
2.34×
Q2 25
1.36×
Q1 25
1.94×
Q4 24
0.62×
Q3 24
1.97×
Q2 24
1.02×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CCSI
CCSI

Segment breakdown not available.

PRCT
PRCT

Handpieces and other consumables$43.0M52%
System sales and rentals$23.4M28%
Other$11.1M13%
Service$5.6M7%

Related Comparisons